Search 

Kawin Technology is a Chinese biopharma engaging in liver disease and virus-related disease. 
The turnover in 2019 is over 800 million RMB (115 millon USD). 
We are now in IPO process and projected to be listed in China this year. 

What we are looking for:
Antivirals and liver disease: early staged in-licensing  
Technical collaboration, out-licensing

Baiyu , founded in 2005, is a pharmaceutical enterprise engaged in developing, manufacturing and distributing of high-quality pharmaceutical products and APIs. With about 1000 employees, Baiyu now has 6 subsidiaries including Golden Ginkgo Pharmaceutical Co., Ltd., Ginkgolide Pharmaceuticals Co., Ltd., Sunshine Ginkgo Agriculture Co.Ltd., Sichuan Yu Jian Pharmaceutical Co., Ltd. and Ginkgo Yukang Informatics Co.,Ltd., Ginkgo Yuda Pharmaceutical Co.,Ltd., et al.

Currently,we have 8 finished pharmaceutical products and 2 APIs on the market. Based on Quality-by-Design concept, our manufacturing sites strictly comply with cGMP and EU GMP. Ginkgolide injection, Enoxaparin sodium injection, Lansoprazole for injection are our main products.

Baiyu is growing fastly and has been awarded“National High-tech Enterprise”,“Sichuan Famous Brand”and“Enterprises with the most investment value in Chinese pharmaceutical industry”in 3 consecutive years.

The culture of kindness, Taiji and phoenix leads the way we behave and our vision is to constantly benefiting mankind to enjoy life-long well-being.

Sino Biopharmaceutical Limited and its subsidiaries are the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the full industry chain of pharmaceutical R&D platforms, intelligent production and strong sales systems. Its product offerings include a variety of biological drugs and chemical drugs, and it occupies an advantageous position in many potential therapeutic fields such as liver disease, tumors, cardiovascular and cerebrovascular diseases, orthopedics, digestive system, immune and respiratory diseases.

The company was listed on the Hong Kong Stock Exchange in 2000; selected as a component stock of the China Index of the MSCI Global Standard Index in 2013; selected as a component stock of the Hang Seng Index in 2018; selected as a component stock of the Hang Seng China Enterprises Index in 2019; and selected as a component stock of the Stock Connect Biotech 50 Index on the Hong Kong-Shanghai-Shenzhen Stock Connect and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. It was listed in the "Top 50 Global Pharmaceutical Companies" published by the authoritative American magazine "PharmExec" for two consecutive years in 2019 and 2020, and was also listed as one of the "Top 50 Best Companies in Asia Pacific" by Forbes (Asia) for four consecutive years from 2016 to 2019.

ChiaTai Tianqing Pharmaceutical Group Co., Ltd., the core company of Sino Pharmaceutical, ranked 6th in the 2019 China Chemical Pharmaceutical Industry Top 100 Comprehensive Strength List, Beijing Tide Pharmaceutical Co., Ltd. ranked 32nd; Nanjing ChiaTai Tianqing ranked 40th; ChiaTai Fenghai ranked 74th; and ChiaTai Pharmaceutical (Qingdao) ranked 87th. After many years of development, the group has become an important force leading the innovation and development of China's pharmaceutical technology and industry.

The company has been making outstanding achievements and has shown robust growth, which is inseparable from its great emphasis on R&D and innovation. The company currently leads the industry in R&D investment and product innovation capabilities. Based on policy trends, it focuses on the expansion of related areas centering around its main business, and has laid out a comprehensive general health development strategy. It has been continuously improving the efficiency of enterprise management, R&D, production and marketing by harnessing technologies and methods such as Big Data, artificial intelligence and fintech.

Sino Biopharmaceutical will inherit the values of "benefiting the country, the people, and the enterprise" held by Chiatai Group, undertake the mission of "health, happiness and longevity". Based on independent innovation, it will introduce global innovative technologies to consolidate its leading position in the Chinese market. It is hoped that insightful talents can share the development results of the pharmaceutical and healthcare industry. Let's join hands for a win-win future!